Press Releases
BW Energy: Appraisal confirms material Hibiscus field reserve increase
Reference is made to the stock exchange notice by BW Energy on 20 May 2024 announcing a substantial oil discovery on the northern flank of the Hibiscus field.
BW Energy has now concluded the drilling and the logging of the DHIBM-7P pilot well, confirming a substantial oil discovery with good reservoir quality and a material uplift to the Hibiscus area.
The Company’s preliminary evaluation... (continue reading...)
GENEVA, SWITZERLAND / ACCESSWIRE / June 3, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that interim Chief Executive Officer Michelle Lock has completed her transitional mandate with the Company. Her contract was not renewed upon its expiration on May 31, 2024.
... (continue reading...)- CHMP opinion paves the way for Marketing Authorisation approval by the European Commission, currently anticipated in early August 2024.
- When approved, AKANTIOR will be the first licensed medicinal product for the treatment of acanthamoeba keratitis, a rare, severe eye infection that often results in blindness and eye loss.
- Phase III ODAK study demonstrated 87% of patients receiving AKANTIOR were cured within a median time of 4 months.
- AKANTIOR will be... (continue reading...)
Dublin, Ireland--(Newsfile Corp. - June 3, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (Cosmo) with its Cosmo Intelligent Medical Devices division (Cosmo IMD) is consolidating its strategy to accelerate the adoption of responsible and regulated AI in healthcare, obtaining pragmatic results in its mission to address unmet clinical needs and improve patient outcomes.
GI Genius" has been conceived and is being designed, developed,... (continue reading...)
Dublin, Ireland--(Newsfile Corp. - June 3, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (Cosmo) with its Cosmo Intelligent Medical Devices division (Cosmo IMD) is consolidating its strategy to accelerate the adoption of responsible and regulated AI in healthcare, obtaining pragmatic results in its mission to address unmet clinical needs and improve patient outcomes.
GI Genius" has been conceived and is being designed, developed,... (continue reading...)
More Press Releases
View Older Stories-
Dreya Starr's Newest Releases!
-
Pickleball Paradise hits the musical market
-
Formosa Laboratories Completes the Acquisition of Synchem to Expand North American CDMO Footprint
-
New Kearney report: Chemicals M&A rebound expected in the next 12 to 18 months with return of sustainability goals, predict more than 50% of industry execs
-
UAE TO HOST GAMES OF THE FUTURE 2025
-
Start of Day Message
-
Market Update
-
New data with daridorexant to be presented at SLEEP 2024
-
Corbion reports the progress of its € 20 million share buyback program 27 May – 31 May 2024
-
ALK presents positive phase 3 paediatric trial data offering new hope for children with respiratory allergies
-
Ipsen initiates a share buy-back program to cover its free employee share-allocation plan
-
Ontex finalizes the divestment of its business in Pakistan
-
Asia Green Fund U.S.-China Green Fund I Partner Conference 2023 is Successfully Held in Beijing
-
Flash News: OKX to Support Mina Protocol's Upgrade
-
Flash News: OKX to Support Mina Protocol's Upgrade
-
Burning Rock Regains Compliance with NASDAQ Minimum Bid Price Requirement
-
Upcoming Acer Swift Series Laptops to Feature Models with New AMD Ryzen AI 300 Series Processors
-
ASHTON-DRAKE RELEASES PREMIUM "RUDOLPH THE RED-NOSED REINDEER®" MASTERPIECE FIGURE COLLECTION
-
HO CHI MINH CITY RIVER FESTIVAL EXPANDS IN SCALE, IGNITING SUMMER TOURISM IN 2024
-
NetAlly Unveils Next Generation LinkRunner® AT Network and Cable Testers
-
Private equity finds a footing but still searching for momentum as two-year slump bottoms out--Bain & Company's PE Midyear Report
-
Triumph Motorcycle Dealers Ranked First in Industry Study for Providing Quick and Easy Service Appointments
-
Sigma 28-45mm F1.8 Full Frame DG DN Art Lens Announced; YouTube Video First Look, Learn More Info at B&H Photo Video
-
ARUP Files Declaration to Support Lawsuit Challenging the FDA's Rule to Regulate Lab-Developed Tests
-
10 Fitness Guarantees Uninterrupted Gym Access with SARA, Even After Hours
-
IXOPAY Appoints Brady Harris as CEO to Drive Global Payments Growth
-
BIOPHTA raises 6.5 million Euros Seed Funding to transition its New Standard of Care for Eye Diseases to the Clinical stage
-
MGI Tech's DNBSEQ-E25 and G99 Platforms Set Record for Sequencing Applications on Mount Everest
-
The9 Signed a Definitive Share Purchase Agreement to Invest in AI-Powered Educational Technology Company
-
AMD Unveils Next-Gen “Zen 5” Ryzen Processors to Power Advanced AI Experiences
-
AMD Accelerates Pace of Data Center AI Innovation and Leadership with Expanded AMD Instinct GPU Roadmap
-
AMD Extends AI and High-Performance Leadership in Data Center and PCs with New AMD Instinct, Ryzen and EPYC Processors at Computex 2024
-
Leads Biolabs' Innovative Cancer Treatment LBL-024, an Anti-PDL1/4-1BB Bispecific Antibody Achieved Outstanding Phase II Results, Has Been Presented in Clinical Science Symposium at 2024 ASCO Ann
-
Appointment of Director to Woodside Board
-
NOTICE OF THE TWENTY-FIFTH ANNUAL GENERAL MEETING OF SHAREHOLDERS
-
2Flo Ventures Announces Addition of Renowned Life Sciences Executive Charlotte Jones-Burton, MD, MS as a Partner
-
Flash News: OKX Launches 100% Fee Rebate Campaign
-
Supermicro Liquid-Cooled AI SuperClusters Will Power Large-Scale AI Data Center in Japan
-
LaVie Care Centers Takes Strategic Actions to Position the Company for Long-Term Success Amidst Challenging Skilled Nursing Operating Environment
-
Innovent Delivers Oral Presentation of Clinical Data of A Randomized Controlled Phase 1b Study Evaluating IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab as Neoadjuvant Treatme
-
Innovent Delivers Oral Presentations at the 2024 ASCO Annual Meeting on Clinical Data of First-in-Class anti-CLDN18.2/CD3 Bispecific Antibody (IBI389) for the Treatment of Advanced Pancreatic Cancer a
-
SATO Technologies Corp. Reports Limited Incident at the Building Hosting Data Center One
-
China Medical University Hospital (CMUH, Taiwan) Signs MOU with Malaysian International Medical University
-
TOYOTA GAZOO Racing and Ogier denied in dramatic finish
-
Keymed Biosciences Announces Long-term Efficacy and Safety Data from a Phase III Clinical Trial of Stapokibart for the Treatment of Moderate-to-severe Atopic Dermatitis
-
Fujitsu Japan and Juntendo University launch joint research for disaster-resilient, digital medical system
-
TECNO exhibits its diverse smartphone and AIoT ecosystem with futuristic AR and AI products at COMPUTEX Taipei 2024, with the concept "Smart of Creation"
-
MSI Unveils New AI and Computing Platforms with 4th Gen AMD EPYC™ Processors at Computex 2024
-
Nissan Demonstrates Autonomous-Drive Mobility Services Progress on Public Roads
-
Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial